U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H32O2
Molecular Weight 304.4669
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DROMOSTANOLONE

SMILES

[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC[C@@]4([H])CC(=O)[C@H](C)C[C@]34C

InChI

InChIKey=IKXILDNPCZPPRV-RFMGOVQKSA-N
InChI=1S/C20H32O2/c1-12-11-20(3)13(10-17(12)21)4-5-14-15-6-7-18(22)19(15,2)9-8-16(14)20/h12-16,18,22H,4-11H2,1-3H3/t12-,13+,14+,15+,16+,18+,19+,20+/m1/s1

HIDE SMILES / InChI
Dromostanolone Propionate (known by the brand names Masteron and Drolban) was invented by Syntex in 1959. About 10 years later it was released on the American market by Lilly as brand name Drolban. The drug was first approved in the USA for use as a treatment of female breast cancer. However, the profile of side-effects included pronouncement of male characteristics in women and when more effective breast cancer treatments came to market drostanolone was gradually phased out. No longer used clinically dromostanolone propionate became very popular in the bodybuilding community. Today dromostanolone propionate remains on the list of approved medications, but it is not being manufactured or sold by pharmaceutical companies. It is still produced illegally by underground labs for use in the bodybuilding community.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Drolban

Approved Use

Unknown
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 day
single, intramuscular
DROMOSTANOLONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg 4 times / day multiple, oral
Dose: 100 mg, 4 times / day
Route: oral
Route: multiple
Dose: 100 mg, 4 times / day
Sources:
unhealthy, adult
n = 9
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 9
Sources:
Disc. AE: Hypertriglyceridemia...
AEs leading to
discontinuation/dose reduction:
Hypertriglyceridemia (5 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypertriglyceridemia 5 patients
Disc. AE
100 mg 4 times / day multiple, oral
Dose: 100 mg, 4 times / day
Route: oral
Route: multiple
Dose: 100 mg, 4 times / day
Sources:
unhealthy, adult
n = 9
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 9
Sources:
PubMed

PubMed

TitleDatePubMed
Endocrinological and pathological effects of anabolic-androgenic steroid in male rats.
2004 Aug
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Intramuscular
In Vitro Use Guide
Unknown
Name Type Language
DROMOSTANOLONE
MI  
Common Name English
DROSTANOLONE [HSDB]
Common Name English
drostanolone [INN]
Common Name English
ANDROSTAN-3-ONE, 17-HYDROXY-2-METHYL-, (2.ALPHA.,5.ALPHA.,17.BETA.)-
Systematic Name English
DROSTANOLONE
HSDB   INN   WHO-DD  
INN  
Official Name English
(2.ALPHA.,5.ALPHA.,17.BETA.)-17-HYDROXY-2-METHYLANDROSTAN-3-ONE
Systematic Name English
Drostanolone [WHO-DD]
Common Name English
DROMOSTANOLONE [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C243
Created by admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
NCI_THESAURUS C2360
Created by admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
WIKIPEDIA Designer-drugs-Drostanolone
Created by admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
DEA NO. 4000
Created by admin on Fri Dec 15 16:14:38 GMT 2023 , Edited by admin on Fri Dec 15 16:14:38 GMT 2023
Code System Code Type Description
WIKIPEDIA
Drostanolone
Created by admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
PRIMARY
MERCK INDEX
m4767
Created by admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C1076
Created by admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
PRIMARY
FDA UNII
7DR7H00HDT
Created by admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
PRIMARY
EPA CompTox
DTXSID6022971
Created by admin on Fri Dec 15 16:14:38 GMT 2023 , Edited by admin on Fri Dec 15 16:14:38 GMT 2023
PRIMARY
HSDB
3319
Created by admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
PRIMARY
RXCUI
23678
Created by admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
PRIMARY RxNorm
PUBCHEM
6011
Created by admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
PRIMARY
MESH
C100263
Created by admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
PRIMARY
DRUG BANK
DB00858
Created by admin on Fri Dec 15 16:14:38 GMT 2023 , Edited by admin on Fri Dec 15 16:14:38 GMT 2023
PRIMARY
EVMPD
SUB06414MIG
Created by admin on Fri Dec 15 16:14:38 GMT 2023 , Edited by admin on Fri Dec 15 16:14:38 GMT 2023
PRIMARY
INN
1159
Created by admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
PRIMARY
SMS_ID
100000081008
Created by admin on Fri Dec 15 16:14:39 GMT 2023 , Edited by admin on Fri Dec 15 16:14:39 GMT 2023
PRIMARY
CHEBI
34838
Created by admin on Fri Dec 15 16:14:38 GMT 2023 , Edited by admin on Fri Dec 15 16:14:38 GMT 2023
PRIMARY
CAS
58-19-5
Created by admin on Fri Dec 15 16:14:38 GMT 2023 , Edited by admin on Fri Dec 15 16:14:38 GMT 2023
PRIMARY
ChEMBL
CHEMBL1201048
Created by admin on Fri Dec 15 16:14:38 GMT 2023 , Edited by admin on Fri Dec 15 16:14:38 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-367-9
Created by admin on Fri Dec 15 16:14:38 GMT 2023 , Edited by admin on Fri Dec 15 16:14:38 GMT 2023
PRIMARY